Editors

Picture1

Prof. Sven Francque

Chairman

Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.

Read More
Picture2

Prof. Manal F. Abdelmalek

Orthopedic Physical Therapy Resident

Manal F. Abdelmalek, MD, MPH is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic,

Read More
Picture3

Prof. Christopher Byrne

Orthopedic Physical Therapy Resident

Professor Byrne trained as a clinical scientist in the UK and the US, at Cardiff, Cambridge and Stanford Universities. He undertook a PhD studying liver lipid metabolism at Cambridge University. He was a post-doctoral fellow at Stanford University and then an MRC fellow at Cambridge University.

Read More
Picture4

Prof. Kenneth Cusi

Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville (2011-present). He is also a faculty and researcher at the Endocrinology, Diabetes and Metabolism Division at the Veterans Administration Medical Center at

Read More
Picture5

Prof. Jean-François Dufour

Jean-Francois Dufour studied mathematics at the University of Geneva, Switzerland, and received his medical degree from the Geneva Medical School. After training in internal medicine at the University Hospital Geneva and the University Hospital Bern, he joined the laboratory of Professor I.

Read More
Picture6

Prof. Frank Sacks

Dr. Sacks is Professor of Cardiovascular Disease Prevention in the Nutrition Department of Harvard Chan School of Public Health; Professor of Genetics & Complexes Diseases; and Professor of Medicine at Harvard Medical School. Dr. Sacks led the panel designing the DASH Study, which crafted a healthful

Read More
Picture7

Prof. Gyongyi Szabo

Gyongyi Szabo, MD, PhD is the Worcester Foundation for Biomedical Research Endowed Chair, Professor and Vice Chair of Medicine and Associate Provost at the University of Massachusetts Medical School. Dr. Szabo is an internationally recognized leader in the field of liver immunology and inflammation.

Read More
Prof.Frank Tacke - CC13 Neuberufung-Medizinische Klinik m.S. Hepatologie und Gastroenterologie CVK - Forschung

Prof. Frank Tacke

Frank Tacke was originally educated at the medical school in Hannover, Germany, and Baylor College of Medicine, Houston, TX. Later he stayed at University of Texas, M.D. Anderson Cancer Center in Houston, working on new gene therapy strategies (1998-1999) as well as for a post-doctoral research training (2004-2006) at

Read More
Michael Roden

Prof. Michael Roden

Professor Dr. Michael Roden is Chair of Endocrinology and Metabolic Diseases, Heinrich-Heine University, Director of the Division of Endocrinology and Diabetology, University Clinics Düsseldorf and CEO of the German Diabetes Center (DDZ). He was trained at University of Vienna and Yale University. His translational studies address insulin resistance, energy metabolism and nonalcoholic fatty liver diseases and diabetes mellitus in humans, specifically using noninvasive technologies.

Read More

Michael Roden

University training and degree

1979-1986 : Medicine, University of Vienna, Austria

 Advanced academic qualifications

Habilitation: 1994, Modulation of hepatic insulin sensitivity, University of Vienna, Austria

Graduation: 1986 Dr. med. univ., University of Vienna, Austria

Frank Tacke

Frank Tacke was originally educated at the medical school in Hannover, Germany, and Baylor College of Medicine, Houston, TX. Later he stayed at University of Texas, M.D. Anderson Cancer Center in Houston, working on new gene therapy strategies (1998-1999) as well as for a post-doctoral research training (2004-2006) at the Mount Sinai Medical Center, New York, working on monocyte/macrophage and dendritic cell biology. Since 2006, he is a clinical physician and leader of a research laboratory at the University Hospital Aachen, Germany. He is board-certified in Internal Medicine, Gastroenterology and Critical Care Medicine. His research interests are: Clinical and Experimental Hepatology, Liver Immunology, Viral Hepatitis, Gastroenterology, Critical Care Medicine, and Monocyte/Macrophage Biology. In 2012, Frank Tacke was appointed as an Associate Professor (W2-professorship) at the RWTH University Aachen. He has (co‑)authored >180 peer-reviewed original and review articles.

Gyongyi Szabo

Gyongyi Szabo, MD, PhD is the Worcester Foundation for Biomedical Research Endowed Chair, Professor and Vice Chair of Medicine and Associate Provost at the University of Massachusetts Medical School.  Dr. Szabo is an internationally recognized leader in the field of liver immunology and inflammation. Her clinical investigations focus on alcoholic hepatitis, non-alcoholic fatty liver disease and viral hepatitis. She is the lead investigator on an NIH-supported multicenter clinical trial in alcoholic hepatitis. Her laboratory studies the cellular and molecular mechanisms of inflammation and innate immunity in liver injury to identify therapeutic targets in liver diseases including non-alcoholic liver disease and NASH. Her investigations recently revealed the importance of micro-RNAs and extracellular vesicles in liver diseases.  Dr. Szabo’s is member of the Hungarian Academy of Sciences, and fellow of the AASLD, AGA and the American College of Physicians (ACP). Dr. Szabo serves on advisory boards of several federal agencies and leading academic institutions. Dr. Szabo served on the Governing Board and as President of the American Association for the Study of Liver Diseases (AASLD) in 2015 and she the inaugural Editor-in-Chief of Hepatology Communications.

Frank Sacks

Dr. Sacks is Professor of Cardiovascular Disease Prevention in the Nutrition Department of Harvard Chan School of Public Health; Professor of Genetics & Complexes Diseases; and Professor of Medicine at Harvard Medical School. Dr. Sacks led the panel designing the DASH Study, which crafted a healthful eating pattern and demonstrated that it lowered blood pressure more effectively than any previous dietary treatment.  Subsequently Dr. Sacks led the DASH-Sodium study, which determined the dose-response effect of dietary sodium on BP. These multi-center National Heart Lung and Blood Institute trials found major beneficial additive effects of low salt and a dietary pattern rich in fruits and vegetables on blood pressure. Dr. Sacks was Co-Chair of the OmniHeart Trial that found that variations of the DASH diet that are higher in protein or unsaturated fat and lower in carbohydrate further improved blood pressure and lipid risk factors.  He also led the seminal PoundsLost trial which showed the percentage of calories from fat or carbohydrate had no effect on long term weight loss. Dr. Sacks led the OmniCarb trial, which studied the effects of glycemic index and load on cardiovascular risk factors. Currently, he is co-investigator of the MIND study, a randomized trial of a diet that combines features of the Mediterranean and DASH diets to preserve cognition in older people, funded by the National Institute on Aging.

Dr. Sacks’s laboratory has studied the role of apolipoproteins in atherogenic lipoprotein metabolism in obesity and hypertriglyceridemia. He authored over 30 research papers on apoC-3 and/or apoE. Recently he discovered that a type of HDL that contains apolipoprotein C-III predicted higher rates of heart disease and diabetes, the opposite to the protective relation for the total HDL; and impaired HDL function in reverse cholesterol transport.

Dr. Sacks teaches at Harvard School of Public Health as course director for nutritional biochemistry. Dr. Sacks received the 2011 Research Achievement Award of the American Heart Association for lifetime research accomplishment.

Jean-François Dufour

Jean-Francois Dufour studied mathematics at the University of Geneva, Switzerland, and received his medical degree from the Geneva Medical School. After training in internal medicine at the University Hospital Geneva and the University Hospital Bern, he joined the laboratory of Professor I. Arias at Tufts University in Boston, Massachusetts, USA where he studied the effects of calcium signalling on bile canaliculus. He then returned to the clinic to complete a gastroenterology fellowship with Professor M. Kaplan at the New England Medical Center, also at Tufts University. In 1997, Professor Dufour established his own laboratory at the University of Bern where he is currently Clinic Director and Full Professor of Hepatology.

Kenneth Cusi

Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville (2011-present). He is also a faculty and researcher at the Endocrinology, Diabetes and Metabolism Division at the Veterans Administration Medical Center at Gainesville, FL.

He received his medical degree and did his internal medicine residency in Buenos Aires, Argentina and completed a fellowship in Endocrinology, Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas.  He moved to San Antonio, Texas (1992) to work on the role of defects in insulin secretion and insulin resistance to the development of type 2 diabetes mellitus (T2DM), as well as on complications associated with T2DM. He later focused on the relationship and underlying mechanisms of nonalcoholic fatty liver disease (NAFLD) in T2DM and its impact on dyslipidemia, diabetes control and cardiovascular disease.  Dr. Cusi has contributed to the field on the underlying mechanisms of NAFLD in obesity and diabetes, and published the first RCT on pioglitazone for NASH for patients with prediabetes or T2DM (Belfort et al, NEJM 2006). This was followed by a recent long-term study confirming its value in this population (Cusi et al, Annals Intern Med 2016).  Dr. Cusi’s current work at the University of Florida centers on discovering the mechanism(s) leading to NASH and searching for novel treatments.

Dr. Cusi has published more than 150 original articles, reviews and book chapters in a broad spectrum of peer-reviewed journals, such as the New England Journal of Medicine, Annals of Internal Medicine, Proceeding of the National Academy of Science, Journal of Clinical Investigation, Diabetes, Diabetes Care, J Clinical Endocrinology and Metabolism, American Journal of Physiology, Hepatology, Gastroenterology and others. He is an associate editor and reviewer for many journals in the fields of endocrinology, metabolism, diabetes and liver disease.  He is a frequent invited lecturer to national and international meetings on the role of obesity and NAFLD in T2DM.  He is a member of the NIH Clinical and Integrative Diabetes and Obesity (CIDO) study section and contributed to the panel of the 2012 and 2017 NASH guidelines of the American Association for the Study of Liver Diseases. In 2015 Dr. Cusi received 2 prestigious awards by the University of Florida, the Exemplary Teacher Award and the Clinical Research Award for outstanding achievement, research discovery, and productivity from the College of Medicine.

Christopher Byrne

Professor Byrne trained as a clinical scientist in the UK and the US, at Cardiff, Cambridge and Stanford Universities. He undertook a PhD studying liver lipid metabolism at Cambridge University. He was a post-doctoral fellow at Stanford University and then an MRC fellow at Cambridge University. He was appointed to the Chair of Endocrinology & Metabolism at the University of Southampton in 1999 and was inaugural Director of the Wellcome Trust Clinical Research Facility at Southampton until 2004. He is currently Principal Investigator within the NIHR Southampton Biomedical Research Centre and is Consultant Metabolic Physician at University Hospitals Southampton. He has published ~300 publications related to metabolic syndrome and NAFLD and he was a former recipient of the Dorothy Hodgkin prize awarded by Diabetes UK for international research excellence related to diabetes.

Manal F. Abdelmalek

Manal F. Abdelmalek, MD, MPH is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic, Scottsdale AZ and Rochester, MN. She obtained a MPH degree with emphasis in epidemiology, public health and clinical investigation at the University of Florida, Gainesville, Florida. Since first reporting NASH as a case of cryptogenic cirrhosis over 20 years ago, her research area of interest has focused on risk factors for NAFLD acquisition, fibrosis progression, and discovery of new and novel therapeutic interventions. She has expertise in the design and conduct of investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD. Her expertise includes transitioning new compounds to first-in-man early phase studies and the translation of clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a standing member of NASH Clinical Research Network (NASH CRN) and principal investigator on several investigator-initiated and industry-sponsored studies for NAFLD/NASH. She has over 130 publications authored publications in the field of liver disease, the majority of which are in the area of NAFLD.

Sven Francque

Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France. He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of NASH. He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission. He participates in several clinical trials in the field and was/is as scientific committee member involved in the design of several phase 2 and phase 3 trials in NAFLD. He is senior clinical researcher for the Research Fund of the Flemish government. He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp.